

# Kristina Callis Duffin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5011798/publications.pdf>

Version: 2024-02-01

54  
papers

2,180  
citations

304368

22  
h-index

243296

44  
g-index

63  
all docs

63  
docs citations

63  
times ranked

3010  
citing authors

#	ARTICLE	IF	CITATIONS
1	Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. <i>Nature Communications</i> , 2017, 8, 15382.	5.8	251
2	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.5	194
3	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	3.5	182
4	Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. <i>Nature Communications</i> , 2015, 6, 6916.	5.8	154
5	Obesity in Early Adulthood as a Risk Factor for Psoriatic Arthritis. <i>Archives of Dermatology</i> , 2010, 146, 721-6.	1.7	139
6	Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007394.	1.3	115
7	microRNAs in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 365-371.	0.3	108
8	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	1.0	93
9	The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 667-674.	0.6	89
10	Genetics of psoriasis and psoriatic arthritis: update and future direction. <i>Journal of Rheumatology</i> , 2008, 35, 1449-53.	1.0	79
11	Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 604-608.	0.6	70
12	A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). <i>Journal of Investigative Dermatology</i> , 2020, 140, 1784-1793.e2.	0.3	61
13	Work Productivity Loss and Fatigue in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 1670-1674.	1.0	54
14	Genetic Variations in Cytokines and Cytokine Receptors Associated with Psoriasis Found by Genome-Wide Association. <i>Journal of Investigative Dermatology</i> , 2009, 129, 827-833.	0.3	51
15	Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1973-1981.	0.3	45
16	The International Dermatology Outcome Measures Group: Formation of patient-centered outcome measures in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 345-348.	0.6	44
17	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	1.0	43
18	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	1.0	42

#	ARTICLE	IF	CITATIONS
19	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. <i>Human Molecular Genetics</i> , 2017, 26, 4301-4313.	1.4	41
20	Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018, 154, 1137.	2.0	41
21	Fine mapping of eight psoriasis susceptibility loci. <i>European Journal of Human Genetics</i> , 2015, 23, 844-853.	1.4	25
22	The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1227-1229.	1.0	18
23	Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 86-93.	0.6	16
24	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	1.0	14
25	Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 923-930.	0.6	11
26	Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. <i>Archives of Dermatological Research</i> , 2018, 310, 701-710.	1.1	10
27	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018, 234, 157-165.	0.9	10
28	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	1.0	10
29	Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 701-702.	1.0	9
30	Cliniciansâ€™ perspectives on the integration of electronic patient-reported outcomes into dermatology clinics: a qualitative study. <i>Quality of Life Research</i> , 2021, , .	1.5	9
31	International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , 2016, 43, 959-960.	1.0	8
32	Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2013 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1240-1243.	1.0	7
33	Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1559-1565.	1.0	7
34	Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 323-338.	3.3	6
35	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2021, 237, 151-157.	0.9	6
36	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201671.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Clinical and pathologic factors associated with deep transection of biopsies of invasive melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 766-768.	0.6	4
38	Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 54-61.	0.6	4
39	Assessing psoriasis severity: Psychometric validation of overall physician global assessment. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 637-638.	0.6	4
40	GRAPPA 2015 Research and Education Project Reports. <i>Journal of Rheumatology</i> , 2016, 43, 979-985.	1.0	3
41	Comparative Assessment of PASI and Variations of PGA $\bar{A}$ –BSA as Measures of Psoriasis Severity. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017, 2, 113-118.	0.3	3
42	Pustular Psoriasis and Associated Musculoskeletal Disorders. <i>Journal of Rheumatology</i> , 2021, , jrheum.201673.	1.0	3
43	GRAPPA 2017 Project Report. <i>Journal of Rheumatology</i> , 2018, 94, 48-51.	1.0	3
44	Increased Prevalence of Sleep Disorders and Medical Comorbidities in Psoriatic Arthritis Patients Compared with Patients with and without Psoriasis. <i>Psoriasis Forum</i> , 2011, 17a, 209-215.	0.1	2
45	Presidential Round Table: A Report from the GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 986-989.	1.0	2
46	GRAPPA 2016 Project Report. <i>Journal of Rheumatology</i> , 2017, 44, 706-710.	1.0	2
47	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2021, , jrheum.201679.	1.0	2
48	Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases. <i>Journal of Rheumatology</i> , 2022, , jrheum.211330.	1.0	2
49	Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018, 234, 112-119.	0.9	1
50	Addressing Hypertension in Patients With Psoriasis: Review and Recommendations. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 129-138.	0.3	1
51	Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2021, , jrheum.201666.	1.0	0
52	Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2022, , jrheum.211317.	1.0	0
53	Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, , jrheum.211337.	1.0	0
54	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. <i>Journal of Rheumatology</i> , 2022, , .	1.0	0